What is SpineThera?
SpineThera operates as a specialized clinical-stage biotechnology firm dedicated to the development of innovative therapeutic solutions for radicular leg pain. The company's flagship asset, SX600, utilizes advanced Faros technology to facilitate the sustained release of dexamethasone via a single epidural injection. This approach is designed to provide durable relief for patients, a critical advancement given the current absence of FDA-approved pharmacological agents specifically indicated for epidural administration in lumbar radicular pain cases. With successful Phase 2 clinical data, SpineThera is effectively bridging the gap between traditional surgical interventions and short-term palliative care, establishing a robust market position within the orthopedic and pain management landscape.
How much funding has SpineThera raised?
SpineThera has raised a total of $2.9M across 2 funding rounds:
Private Equity
$585K
Private Equity
$2.4M
Private Equity (2014): $585K, investors not publicly disclosed
Private Equity (2015): $2.4M, investors not publicly disclosed
Key Investors in SpineThera
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SpineThera?
Following this major enterprise-level funding, SpineThera is expected to accelerate its clinical development roadmap, focusing on the transition toward late-stage trials and regulatory engagement. The strategic deployment of this capital will likely prioritize the scaling of manufacturing capabilities for the SX600 platform and the expansion of clinical trial sites to support a potential New Drug Application. As the company navigates the complexities of the regulatory environment, the focus remains on validating the long-term efficacy and safety profile of its sustained-release technology. Investors are closely monitoring the firm's ability to maintain its competitive advantage in a sector where non-surgical, long-acting pain relief remains a high-value, underserved clinical frontier.
See full SpineThera company page
